Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
EMERYVILLE, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that management will be presenting at the H.C. Wainwright Global...
-
Q4 2017 GAAP revenue of $80.6 million, compared with GAAP revenue of $22.2 million for Q4 2016 Q4 2017 operating income of $33.0 million compared with Q4 2016 operating loss of $34.5 millionQ4 2017...
-
Amyris to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15, 2018
EMERYVILLE, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the fourth quarter and fiscal year ended December 31, 2017 after market close on...
-
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that Aprinnova, its joint venture with NIKKOL GROUP (“NIKKOL”),...
-
EMERYVILLE, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Biossance™, the consumer beauty brand from Amyris, Inc. (NASDAQ:AMRS), today announced its innovative line of clean beauty products will be...
-
Starts 2018 with Strong Continued Momentum EMERYVILLE, Calif., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced two grants that have...
-
HEERLEN, the Netherlands and EMERYVILLE, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Royal DSM (AEX:DSM.AS), a global science-based company active in health, nutrition and materials and Amyris, Inc....
-
EMERYVILLE, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) today announced that it will hold a special teleconference to provide additional details on its recently announced...
-
HEERLEN, The Netherlands and EMERYVILLE, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Royal DSM (AEX:DSM.AS), a global science-based company active in health, nutrition and materials and Amyris, Inc....
-
Q3 2017 GAAP revenues of $24.2 million (excludes $8.3 million for an upfront license agreement with Royal DSM executed in Q3 and fully paid early in Q4 2017) and Non-GAAP Q3 revenues of $32.5 million...